407 related articles for article (PubMed ID: 24521857)
1. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
2. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
[TBL] [Abstract][Full Text] [Related]
3. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
4. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine cancer. Closing the GAPP on predicting metastases.
Eisenhofer G; Tischler AS
Nat Rev Endocrinol; 2014 Jun; 10(6):315-6. PubMed ID: 24686203
[TBL] [Abstract][Full Text] [Related]
6. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
[TBL] [Abstract][Full Text] [Related]
8. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
9. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
10. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
[TBL] [Abstract][Full Text] [Related]
11. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
[TBL] [Abstract][Full Text] [Related]
12. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
Wang LL; Wei XJ; Zhang QC; Li F
Ann Diagn Pathol; 2022 Oct; 60():151981. PubMed ID: 35660808
[TBL] [Abstract][Full Text] [Related]
13. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
14. MITOCHONDRIA: Succinate dehydrogenase subunit B-associated phaeochromocytoma and paraganglioma.
Dona M; Neijman K; Timmers HJLM
Int J Biochem Cell Biol; 2021 May; 134():105949. PubMed ID: 33609747
[TBL] [Abstract][Full Text] [Related]
15. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
Benn DE; Croxson MS; Tucker K; Bambach CP; Richardson AL; Delbridge L; Pullan PT; Hammond J; Marsh DJ; Robinson BG
Oncogene; 2003 Mar; 22(9):1358-64. PubMed ID: 12618761
[TBL] [Abstract][Full Text] [Related]
16. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
Gupta S; Zhang J; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers.
Srirangalingam U; Walker L; Khoo B; MacDonald F; Gardner D; Wilkin TJ; Skelly RH; George E; Spooner D; Monson JP; Grossman AB; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
Clin Endocrinol (Oxf); 2008 Oct; 69(4):587-96. PubMed ID: 18419787
[TBL] [Abstract][Full Text] [Related]
18. Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas.
Lee JP; Hung YP; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
Histopathology; 2017 Oct; 71(4):503-510. PubMed ID: 28464318
[TBL] [Abstract][Full Text] [Related]
19. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
[TBL] [Abstract][Full Text] [Related]
20. Pathology and genetics of phaeochromocytoma and paraganglioma.
Turchini J; Cheung VKY; Tischler AS; De Krijger RR; Gill AJ
Histopathology; 2018 Jan; 72(1):97-105. PubMed ID: 29239044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
